body. However, one strain was agglutinated by FDA/F3 and polyclonal anti-Agg 3 reagents but not by the CAMR anti-Agg 3.
The CAMR anti-Agg 2 and FDA/F2 antibodies showed similar sensitivities, whereas CAMR anti-Agg 3 was clearly superior to FDA/F3. CAMR anti-Agg 2 and anti-Agg 3 and FDA/F2 could therefore be adopted as standard serotyping reagents. The CAMR anti-Agg 1 was inferior to the polyclonal reagent in sensitivity but may not have been detecting the same antigens. The identity of Agg 1 detected by polyclonal reagents has not been conclusively resolved and its epidemiological relevance is unclear. The CAMR and FDA reagents detect fimbrial components (1, 2) , although there may be incomplete overlap of specificity. This and differences in isotype and/or subclass could explain the discrepancies noted in this and in the previous study.
